卡瑞利珠单抗联合化疗治疗老年非小细胞肺癌患者的临床疗效及对血清CY211、MMP-9表达的影响  

Clinical efficacy of carrilizumab combined with chemotherapy in elderly patients with non-small cell lung cancer and effect on expression of serum CY211 and MMP-9

作　　者：李丽 胡筱 曹主根 LI Li;HU Xiao;CAO Zhu-gen(Department of Oncology,The First People's Hospital of Suqian,Suqian Jiangsu 223800,China)

机构地区：[1]宿迁市第一人民医院肿瘤科,江苏宿迁223800

出　　处：《临床和实验医学杂志》2023年第22期2380-2383,共4页Journal of Clinical and Experimental Medicine

基　　金：江苏省青年医学人才项目(编号:QNRC2016480)。

摘　　要：目的探讨卡瑞利珠单抗联合化疗治疗老年非小细胞肺癌(NSCLC)的临床疗效及对血清细胞角蛋白19片段抗原211(CY211)、基质金属蛋白酶9(MMP-9)表达的影响。方法采用回顾性研究方法,选取2020年1月至2022年12月在宿迁市第一人民医院肿瘤科治疗的老年NSCLC患者100例,根据治疗方法不同分为观察组和对照组,各50例。观察组接受卡瑞利珠单抗联合化疗治疗,对照组仅进行化疗,21 d为1周期。治疗3个周期后对两组患者临床疗效、CY211、MMP-9表达水平及卡氏生存质量(KPS)评分、不良反应情况进行比较。结果观察组患者的治疗总有效率为58.00%,明显高于对照组(34.00%),差异有统计学意义(P<0.05)。治疗后,两组患者的CY211、MMP-9水平均明显低于治疗前,且观察组患者CY211、MMP-9水平分别为(2.49±0.72)μg/L、(989.26±76.18)ng/mL,均显著低于对照组[(3.29±1.08)μg/L、(1463.15±80.21)ng/mL],差异均有统计学意义(P<0.05)。治疗后,两组患者的KPS评分均明显高于治疗前,且观察组KPS评分为(79.16±9.58)分,显著高于对照组[(72.32±10.04)分],差异均有统计学意义(P<0.05)。观察组不良反应发生率为58.00%,与对照组(50.00%)比较,差异无统计学意义(P>0.05)。结论卡瑞利珠单抗联合化疗治疗老年NSCLC可有效提高临床疗效,降低CY211、MMP-9水平,提高患者化疗后生活质量水平,且安全性较高,是当前较为理想的治疗方案。Objective To investigate the efficacy of carrilizumab combined with chemotherapy in elderly non-small cell lung cancer(NSCLC)and the effect on the expression of serum cytokeratin 19 fragment antigen 211(CY211)and matrix metalloproteinase 9(MMP-9).Methods A retrospective study was conducted to select 100 elderly NSCLC patients who were treated in the Department of Oncology,The First People's Hospital of Suqian from January 2020 to December 2022.According to the treatment methods,they were divided into an observation group and a control group,with 50 cases in each group.The observation group received carrilizumab combined with chemotherapy,while the control group only received chemotherapy for 21 days.After three cycles of treatment,the clinical efficacy,expression levels of CY211 and MMP-9,Karnofsky quality of life(KPS)score and adverse reactions of the two groups were compared.Results The total effective rate of treatment in the observation group was 58.00%,which was significantly higher than that in the control group(34.00%),the difference was statistically significant(P<0.05).After treatment,the levels of CY211 and MMP-9 in two groups were significantly lower than before treatment,and the levels of CY211 and MMP-9 in the observation group were(2.49±0.72)μg/L,(989.26±76.18)ng/mL,respectively,which were significantly lower than those in the control group[(3.29±1.08)μg/L,(1463.15±80.21)ng/mL],the differences were statistically significant(P<0.05).After treatment,the KPS scores of two groups were significantly higher than those before treatment,and the KPS score of the observation group was(79.16±9.58)points,which was significantly higher than that of the control group[(72.32±10.04)points],the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 58.00%,and there was no statistically significant difference compared to the control group(50.00%)(P>0.05).Conclusion Carrilizumab combined with chemotherapy in the treatment of elderly NSCLC can effectivel

关 键 词：老年人 非小细胞肺癌 卡瑞利珠单抗 免疫治疗 化疗 CY211 MMP-9 

分 类 号：R734.2[医药卫生—肿瘤]